Background
Aging produces parallel deteriorations in both the GH/IGF-1 axis (somatopause) and immune function (immunosenescence). These are not independent processes — GH and IGF-1 receptors are expressed on immune cells, and GH directly promotes thymic function, T-cell proliferation, and natural killer (NK) cell cytotoxicity. The convergence of GH deficiency and immune aging in elderly individuals raises the question of whether restoring GH secretion can simultaneously address immunosenescence.
Khorram, Laughlin, and Yen at UCSD assessed whether prolonged GHRH(1-29) administration — the pharmacological equivalent of sermorelin — could restore immune function parameters in aged men and women as a secondary outcome of GH axis restoration.
Methods
14 age-advanced subjects (8 men, 6 women; mean age 70 years) received nightly subcutaneous GHRH(1-29) at 1 µg/kg for 6 months. Immune parameters assessed included NK cell cytotoxicity (chromium release assay), lymphocyte subset counts (CD3, CD4, CD8), lymphocyte proliferative response to mitogens, and serum cytokines (IL-2, IL-6, TNF-α). GH axis assessed by 24-hour GH sampling and IGF-1.
Key Findings
GH Axis Response:
- IGF-1 increased from 98 ± 12 to 133 ± 15 ng/mL (+35%, p < 0.01)
- 24-hour GH mean concentration increased 2.1-fold vs. pre-treatment baseline
- Pulsatile GH pattern preserved throughout 6 months — no desensitization
Immune Function Restoration:
| Immune Parameter | Pre-Treatment | 6 Months | Change |
|---|---|---|---|
| NK cell cytotoxicity (%) | 18.4 | 25.8 | +40% (p < 0.01) |
| CD4+ T-cells (cells/µL) | 412 | 487 | +18% (p < 0.05) |
| CD4/CD8 ratio | 1.4 | 1.8 | +29% (p < 0.05) |
| Lymphocyte proliferation index | 2.3 | 3.1 | +35% (p < 0.05) |
| IL-6 (pg/mL) | 8.4 | 5.9 | −30% (p < 0.05) |
- NK cell cytotoxicity increase of 40% suggests restoration of innate immune tumor surveillance
- CD4/CD8 ratio improvement indicates normalization of T-cell balance from immunosenescent inversion
- Lymphocyte proliferative capacity improvement reflects enhanced adaptive immune readiness
- IL-6 reduction reflects attenuation of the low-grade chronic inflammation (inflammaging) characteristic of aged subjects
Tolerability:
- No serious adverse events over 6-month treatment
- Mild injection site reactions in 3/14 subjects (transient)
- No autoimmune activation or lymphoproliferative effects
Mechanistic Basis
GH and IGF-1 exert direct immune-trophic effects:
- Thymic involution reversal: GH promotes thymopoiesis and T-cell maturation — aging-related thymic atrophy is partially GH-dependent
- NK cell priming: IGF-1 receptors on NK cells mediate cytotoxicity enhancement; low IGF-1 in aging correlates with reduced NK killing capacity
- IL-6 suppression: GH and IGF-1 signaling reduce NF-κB-driven inflammatory cytokine production, dampening inflammaging
- Lymphocyte proliferation: GH directly stimulates lymphocyte mitogenesis via JAK2/STAT5 signaling
This creates a mechanistic basis for concurrent GH axis and immune restoration with GHRH peptides — a dual benefit not achieved by direct immunomodulatory agents alone.
Clinical Significance
- Immunosenescence as a GH-related consequence: NK cell and T-cell declines in aging are partially GH-deficiency mediated; GHRH restoration addresses both root causes simultaneously
- Cancer surveillance: The 40% NK cytotoxicity improvement has direct implications for tumor immune surveillance — elderly populations have substantially elevated cancer incidence
- Infection susceptibility: CD4+ T-cell restoration and lymphoproliferative capacity improvement address the increased infection vulnerability of the immunosenescent elderly
- Inflammaging attenuation: The 30% IL-6 reduction represents direct intervention in a key driver of age-related chronic disease (cardiovascular disease, cognitive decline, frailty)
Limitations
- Very small sample size (n=14); limited statistical power for detecting effects in subgroups (sex, baseline immune status)
- 6-month duration; long-term immune effects and their durability after GHRH discontinuation unknown
- No randomized placebo control arm (within-subject pre/post design only); confounders including seasonal immune variation cannot be excluded
- GHRH(1-29) dose of 1 µg/kg may not be optimal; dose-response relationships for immune outcomes not established
- Immune assays conducted ex vivo — functional in vivo immune competence (actual infection resistance) not directly assessed